ResearcherChinese PLA General HospitalActive in the last 2 years

Ru Jia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4064-8333; OpenAlex author ID A5101843755. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2024: 1 paper · 2025: 2 papers

Papers 3

First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metast… Co-author DOI 10.1038/s41392-025-02441-2 ↗
Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. Co-author DOI 10.3389/fimmu.2025.1487318 ↗
A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.017 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Guanghai Dai · 2 shared papers, 2024–2025 · strength 0.54
- Paper Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. DOI 10.3389/fimmu.2025.1487318 ↗
- Paper A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic … DOI 10.1016/j.pan.2024.03.017 ↗
Mengjiao Fan · 2 shared papers, 2024–2025 · strength 0.44
- Paper A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic … DOI 10.1016/j.pan.2024.03.017 ↗
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Guochao Deng · 2 shared papers, 2024–2025 · strength 0.44
- Paper A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic … DOI 10.1016/j.pan.2024.03.017 ↗
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Shiyun Chen · 1 shared paper, 2025 · strength 0.30
- Paper Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. DOI 10.3389/fimmu.2025.1487318 ↗
Nan Zhang · 1 shared paper, 2025 · strength 0.30
- Paper Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy. DOI 10.3389/fimmu.2025.1487318 ↗
Yue Ma · 1 shared paper, 2024 · strength 0.24
- Paper A real-world analysis of second-line treatment option, gemcitabine plus anlotinib and anti-PD1, in advanced pancreatic … DOI 10.1016/j.pan.2024.03.017 ↗
Guanghai Dai · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗
Quanli Han · 1 shared paper, 2025 · strength 0.20
- Paper First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 … DOI 10.1038/s41392-025-02441-2 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.